Literature DB >> 19706138

A survey of physicians' reasons to transfuse plasma and platelets in the critically ill: a prospective single-centre cohort study.

A P J Vlaar1, A L in der Maur, J M Binnekade, M J Schultz, N P Juffermans.   

Abstract

Data on the rationality of transfusion practice of fresh frozen plasma (FFP) and platelets in the critically ill are sparse and may contribute to efforts to reduce transfusion rates. To provide insight into determinants of the decision of intensive care unit (ICU)-physicians to transfuse, a survey study was performed. The reasons of ICU-physicians to transfuse FFP and platelets were determined during a 10-week period. Transfusion triggers were assessed, as well as correction of prolonged coagulation test results. Of 310 admissions, 44 patients (14%) received a transfusion of FFP and 35 patients (11%) received a platelet transfusion. In 67% patients, FFPs were transfused in bleeding patients and in 33% in non-bleeding patients. FFP was transfused at a prothrombin time (PT) of 19 s (17-22). After FFP transfusion, PT levels of 15-18, 18-20 and 20-26 s decreased with a median of 0.7, 1.9 and 3.5 s, respectively. On average, 3.2 FFP units were ordered, of which 28% was not transfused. The major reason to transfuse platelets was bleeding. Platelets were transfused at a platelet count of 95 (36-116) x 10(9) L(-1) in bleeding and 13 (10-18) x 10(9) L(-1) in non-bleeding patients. On average, 1.4 platelet units were ordered, of which 20% was not transfused. The agreement between physicians reporting a major bleeding and a definition of bleeding was poor (kappa < 0.10 for FFP and 0.20 for platelets). In conclusion, one-third of FFP transfusions was given to non-bleeding patients. FFP transfusion failed to normalize prolonged coagulation test results in the majority of the patients. Transfusion of platelets was restrictive in non-bleeding patients and liberal in bleeding patients. Education on indications of FFP transfusion and improved identification of bleeding may reduce transfusion rates.

Entities:  

Mesh:

Year:  2009        PMID: 19706138     DOI: 10.1111/j.1365-3148.2009.00928.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  7 in total

1.  Correction of subclinical coagulation disorders before percutaneous dilatational tracheotomy.

Authors:  Denise P Veelo; Alexander P Vlaar; Dave A Dongelmans; Jan M Binnekade; Marcel Levi; Frederique Paulus; Fenny Berends; Marcus J Schultz
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

2.  Prophylactic Plasma Transfusion Is Not Associated With Decreased Red Blood Cell Requirements in Critically Ill Patients.

Authors:  Matthew A Warner; Arun Chandran; Gregory Jenkins; Daryl J Kor
Journal:  Anesth Analg       Date:  2017-05       Impact factor: 5.108

3.  Prophylactic Plasma Transfusion Before Interventional Radiology Procedures Is Not Associated With Reduced Bleeding Complications.

Authors:  Matthew A Warner; David A Woodrum; Andrew C Hanson; Darrell R Schroeder; Gregory A Wilson; Daryl J Kor
Journal:  Mayo Clin Proc       Date:  2016-08       Impact factor: 7.616

Review 4.  Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation.

Authors:  Lise J Estcourt; Michael J Desborough; Carolyn Doree; Sally Hopewell; Simon J Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2017-09-25

5.  A prophylactic fresh frozen plasma transfusion leads to a possible case of transfusion-related acute lung injury.

Authors:  Debasree Banerjee; Rashid Hussain; Jeffrey Mazer; Gerardo Carino
Journal:  BMJ Case Rep       Date:  2014-07-21

Review 6.  Adverse effects of plasma transfusion.

Authors:  Suchitra Pandey; Girish N Vyas
Journal:  Transfusion       Date:  2012-05       Impact factor: 3.157

7.  Transfusion of fresh frozen plasma in non-bleeding ICU patients--TOPIC trial: study protocol for a randomized controlled trial.

Authors:  Marcella C A Müller; Evert de Jonge; M Sesmu Arbous; Angelique M E Spoelstra-de Man; Atilla Karakus; Margreeth B Vroom; Nicole P Juffermans
Journal:  Trials       Date:  2011-12-23       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.